This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jazz Pharmaceuticals plc
Drug Names(s): Type IIa sodium channel antagonist, elpetrigine
Description: JZP-4 is a Type IIa sodium channel antagonist. It is a controlled release formulation of an anticonvulsant that is in the same chemical class as Lamictal (lamotrigine), an antiepileptic/bipolar drug marketed by GlaxoSmithKline.
Deal Structure: Jazz acquired the worldwide rights to the active pharmaceutical ingredient (API) in JZP-4 from GSK in 2004. Pursuant to their agreement with GlaxoSmithKline, Jazz has paid upfront and development milestone payments of $5.0 million, and will pay $5.0 million upon first dosing of a patient in a Phase II clinical trial. The agreement with GlaxoSmithKline provides for $108.5 million in additional development and commercial milestone payments, and royalties on commercial sales.
Partners: GlaxoSmithKline plc
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: